The Experts below are selected from a list of 191388 Experts worldwide ranked by ideXlab platform

Medhat Askar - One of the best experts on this subject based on the ideXlab platform.

  • p099 comparison of ssop versus ngs for typing of hla a b c drb1 drb3 b4 b5 dqa1 dqb1 dpa1 dpb1 toward single pass high resolution hla typing in support of solid organ and hematopoietic cell transplant programs
    Human Immunology, 2018
    Co-Authors: Anajane G. Smith, Shalini Pereira, Wyatt Nelson, Andres Jaramillo, Faisal Khan, Noureddine Berka, Marcelo J Pando, Maria Bettinotti, Medhat Askar
    Abstract:

    Aim Many laboratories use a 2-tier HLA typing process: a first pass intermediate resolution and then high resolution, when clinically necessary. SSP or qPCR provide rapid typing for deceased donor workup; SSOP is widely employed for higher volumes; and Sanger sequencing has been the gold standard for high resolution. However, SSOP and Sanger SBT often yield ambiguous results and resolution is expensive and time consuming. Next generation sequencing offers a single pass technology to achieve unambiguous HLA allele assignments. We compared commercial SSOP and NGS systems with respect to accuracy, turnaround time, effort and resolution level. Methods Five laboratories submitted coded, blinded samples, previously typed by SSOP at each institute, to a separate lab for NGS of HLA-A, B, C at exons 1–7, DRB1, DRB3/4/5, DQA1, DQB1, DPB1 at exons 1–4, and DPA1 at exons 2–4. For up to 24 samples by SSOP or up to 48 samples by NGS, benchwork is completed by one technologist on day 1 with results available for reporting on day 2. Results At the SSOP resolution level, results were concordant except for 11 SSOP assignments in 8 specimens due to false probe reactions at DRB1, DRB5, DQA1, DQB1, and DPB1. NGS identified 21 novel sequences: one with a multi-exon deletion and 20 with SNP polymorphisms in HLA-C, DPA1, DPB1, DQA1, DRB1, DRB3, DRB4, and DRB5 alleles. Across the highly polymorphic HLA-A, B, C, DRB1 loci, only 1% of intermediate resolution, IR, SSOP results were unambiguous. Even higher resolution, HR, SSOP by 1 lab gave only 17% specific allele assignments. In contrast, over 99% of NGS results were specific unambiguous genotypes. Across all loci, NGS typing was specific except for certain discrete diploid ambiguities, also found in SSOP. Conclusions This study provides a compelling rationale for implementing NGS for single pass HLA analysis with accurate, 2 day turnaround, which includes the high resolution, unambiguous genotyping critical for unrelated donor HCT and that may be required for sensitized patients with allele specific antibodies. A.G. Smith: 2. Consultant; Company/Organization; Scisco Genetics Inc. S.E. Pereira: 4. Scientific/Medical Advisor; Company/Organization; Scisco Genetics Inc. C. Pyo: 4. Scientific/Medical Advisor; Company/Organization; Scisco Genetics Inc. W. Nelson: 5. Employee; Company/Organization; Scisco Genetics Inc. M. Bettinotti: 3. Speaker’s Bureau; Company/Organization; One Lambda ThermoFisher. M.Z. Askar: 3. Speaker’s Bureau; Company/Organization; Immucor. 4. Scientific/Medical Advisor; Company/Organization; Illumina. D.E. Geraghty: 6. Stock Shareholder; Company/Organization; Scisco Genetics Inc. Download high-res image (283KB) Download full-size image

  • P099 Comparison of ssop versus ngs for typing of HLA-A, B, C, DRB1, DRB3/B4/B5, DQA1, DQB1, DPA1, DPB1: Toward single pass high resolution hla typing in support of solid organ and hematopoietic cell transplant programs
    Human Immunology, 2018
    Co-Authors: Anajane G. Smith, Shalini Pereira, Andres Jaramillo, Faisal Khan, Noureddine Berka, Marcelo J Pando, Maria Bettinotti, Chul-woo Pyo, Wyatt C. Nelson, Medhat Askar
    Abstract:

    Aim Many laboratories use a 2-tier HLA typing process: a first pass intermediate resolution and then high resolution, when clinically necessary. SSP or qPCR provide rapid typing for deceased donor workup; SSOP is widely employed for higher volumes; and Sanger sequencing has been the gold standard for high resolution. However, SSOP and Sanger SBT often yield ambiguous results and resolution is expensive and time consuming. Next generation sequencing offers a single pass technology to achieve unambiguous HLA allele assignments. We compared commercial SSOP and NGS systems with respect to accuracy, turnaround time, effort and resolution level. Methods Five laboratories submitted coded, blinded samples, previously typed by SSOP at each institute, to a separate lab for NGS of HLA-A, B, C at exons 1–7, DRB1, DRB3/4/5, DQA1, DQB1, DPB1 at exons 1–4, and DPA1 at exons 2–4. For up to 24 samples by SSOP or up to 48 samples by NGS, benchwork is completed by one technologist on day 1 with results available for reporting on day 2. Results At the SSOP resolution level, results were concordant except for 11 SSOP assignments in 8 specimens due to false probe reactions at DRB1, DRB5, DQA1, DQB1, and DPB1. NGS identified 21 novel sequences: one with a multi-exon deletion and 20 with SNP polymorphisms in HLA-C, DPA1, DPB1, DQA1, DRB1, DRB3, DRB4, and DRB5 alleles. Across the highly polymorphic HLA-A, B, C, DRB1 loci, only 1% of intermediate resolution, IR, SSOP results were unambiguous. Even higher resolution, HR, SSOP by 1 lab gave only 17% specific allele assignments. In contrast, over 99% of NGS results were specific unambiguous genotypes. Across all loci, NGS typing was specific except for certain discrete diploid ambiguities, also found in SSOP. Conclusions This study provides a compelling rationale for implementing NGS for single pass HLA analysis with accurate, 2 day turnaround, which includes the high resolution, unambiguous genotyping critical for unrelated donor HCT and that may be required for sensitized patients with allele specific antibodies. A.G. Smith: 2. Consultant; Company/Organization; Scisco Genetics Inc. S.E. Pereira: 4. Scientific/Medical Advisor; Company/Organization; Scisco Genetics Inc. C. Pyo: 4. Scientific/Medical Advisor; Company/Organization; Scisco Genetics Inc. W. Nelson: 5. Employee; Company/Organization; Scisco Genetics Inc. M. Bettinotti: 3. Speaker’s Bureau; Company/Organization; One Lambda ThermoFisher. M.Z. Askar: 3. Speaker’s Bureau; Company/Organization; Immucor. 4. Scientific/Medical Advisor; Company/Organization; Illumina. D.E. Geraghty: 6. Stock Shareholder; Company/Organization; Scisco Genetics Inc. Download : Download high-res image (283KB) Download : Download full-size image

Anajane G. Smith - One of the best experts on this subject based on the ideXlab platform.

  • p099 comparison of ssop versus ngs for typing of hla a b c drb1 drb3 b4 b5 dqa1 dqb1 dpa1 dpb1 toward single pass high resolution hla typing in support of solid organ and hematopoietic cell transplant programs
    Human Immunology, 2018
    Co-Authors: Anajane G. Smith, Shalini Pereira, Wyatt Nelson, Andres Jaramillo, Faisal Khan, Noureddine Berka, Marcelo J Pando, Maria Bettinotti, Medhat Askar
    Abstract:

    Aim Many laboratories use a 2-tier HLA typing process: a first pass intermediate resolution and then high resolution, when clinically necessary. SSP or qPCR provide rapid typing for deceased donor workup; SSOP is widely employed for higher volumes; and Sanger sequencing has been the gold standard for high resolution. However, SSOP and Sanger SBT often yield ambiguous results and resolution is expensive and time consuming. Next generation sequencing offers a single pass technology to achieve unambiguous HLA allele assignments. We compared commercial SSOP and NGS systems with respect to accuracy, turnaround time, effort and resolution level. Methods Five laboratories submitted coded, blinded samples, previously typed by SSOP at each institute, to a separate lab for NGS of HLA-A, B, C at exons 1–7, DRB1, DRB3/4/5, DQA1, DQB1, DPB1 at exons 1–4, and DPA1 at exons 2–4. For up to 24 samples by SSOP or up to 48 samples by NGS, benchwork is completed by one technologist on day 1 with results available for reporting on day 2. Results At the SSOP resolution level, results were concordant except for 11 SSOP assignments in 8 specimens due to false probe reactions at DRB1, DRB5, DQA1, DQB1, and DPB1. NGS identified 21 novel sequences: one with a multi-exon deletion and 20 with SNP polymorphisms in HLA-C, DPA1, DPB1, DQA1, DRB1, DRB3, DRB4, and DRB5 alleles. Across the highly polymorphic HLA-A, B, C, DRB1 loci, only 1% of intermediate resolution, IR, SSOP results were unambiguous. Even higher resolution, HR, SSOP by 1 lab gave only 17% specific allele assignments. In contrast, over 99% of NGS results were specific unambiguous genotypes. Across all loci, NGS typing was specific except for certain discrete diploid ambiguities, also found in SSOP. Conclusions This study provides a compelling rationale for implementing NGS for single pass HLA analysis with accurate, 2 day turnaround, which includes the high resolution, unambiguous genotyping critical for unrelated donor HCT and that may be required for sensitized patients with allele specific antibodies. A.G. Smith: 2. Consultant; Company/Organization; Scisco Genetics Inc. S.E. Pereira: 4. Scientific/Medical Advisor; Company/Organization; Scisco Genetics Inc. C. Pyo: 4. Scientific/Medical Advisor; Company/Organization; Scisco Genetics Inc. W. Nelson: 5. Employee; Company/Organization; Scisco Genetics Inc. M. Bettinotti: 3. Speaker’s Bureau; Company/Organization; One Lambda ThermoFisher. M.Z. Askar: 3. Speaker’s Bureau; Company/Organization; Immucor. 4. Scientific/Medical Advisor; Company/Organization; Illumina. D.E. Geraghty: 6. Stock Shareholder; Company/Organization; Scisco Genetics Inc. Download high-res image (283KB) Download full-size image

  • P099 Comparison of ssop versus ngs for typing of HLA-A, B, C, DRB1, DRB3/B4/B5, DQA1, DQB1, DPA1, DPB1: Toward single pass high resolution hla typing in support of solid organ and hematopoietic cell transplant programs
    Human Immunology, 2018
    Co-Authors: Anajane G. Smith, Shalini Pereira, Andres Jaramillo, Faisal Khan, Noureddine Berka, Marcelo J Pando, Maria Bettinotti, Chul-woo Pyo, Wyatt C. Nelson, Medhat Askar
    Abstract:

    Aim Many laboratories use a 2-tier HLA typing process: a first pass intermediate resolution and then high resolution, when clinically necessary. SSP or qPCR provide rapid typing for deceased donor workup; SSOP is widely employed for higher volumes; and Sanger sequencing has been the gold standard for high resolution. However, SSOP and Sanger SBT often yield ambiguous results and resolution is expensive and time consuming. Next generation sequencing offers a single pass technology to achieve unambiguous HLA allele assignments. We compared commercial SSOP and NGS systems with respect to accuracy, turnaround time, effort and resolution level. Methods Five laboratories submitted coded, blinded samples, previously typed by SSOP at each institute, to a separate lab for NGS of HLA-A, B, C at exons 1–7, DRB1, DRB3/4/5, DQA1, DQB1, DPB1 at exons 1–4, and DPA1 at exons 2–4. For up to 24 samples by SSOP or up to 48 samples by NGS, benchwork is completed by one technologist on day 1 with results available for reporting on day 2. Results At the SSOP resolution level, results were concordant except for 11 SSOP assignments in 8 specimens due to false probe reactions at DRB1, DRB5, DQA1, DQB1, and DPB1. NGS identified 21 novel sequences: one with a multi-exon deletion and 20 with SNP polymorphisms in HLA-C, DPA1, DPB1, DQA1, DRB1, DRB3, DRB4, and DRB5 alleles. Across the highly polymorphic HLA-A, B, C, DRB1 loci, only 1% of intermediate resolution, IR, SSOP results were unambiguous. Even higher resolution, HR, SSOP by 1 lab gave only 17% specific allele assignments. In contrast, over 99% of NGS results were specific unambiguous genotypes. Across all loci, NGS typing was specific except for certain discrete diploid ambiguities, also found in SSOP. Conclusions This study provides a compelling rationale for implementing NGS for single pass HLA analysis with accurate, 2 day turnaround, which includes the high resolution, unambiguous genotyping critical for unrelated donor HCT and that may be required for sensitized patients with allele specific antibodies. A.G. Smith: 2. Consultant; Company/Organization; Scisco Genetics Inc. S.E. Pereira: 4. Scientific/Medical Advisor; Company/Organization; Scisco Genetics Inc. C. Pyo: 4. Scientific/Medical Advisor; Company/Organization; Scisco Genetics Inc. W. Nelson: 5. Employee; Company/Organization; Scisco Genetics Inc. M. Bettinotti: 3. Speaker’s Bureau; Company/Organization; One Lambda ThermoFisher. M.Z. Askar: 3. Speaker’s Bureau; Company/Organization; Immucor. 4. Scientific/Medical Advisor; Company/Organization; Illumina. D.E. Geraghty: 6. Stock Shareholder; Company/Organization; Scisco Genetics Inc. Download : Download high-res image (283KB) Download : Download full-size image

Shalini Pereira - One of the best experts on this subject based on the ideXlab platform.

  • p099 comparison of ssop versus ngs for typing of hla a b c drb1 drb3 b4 b5 dqa1 dqb1 dpa1 dpb1 toward single pass high resolution hla typing in support of solid organ and hematopoietic cell transplant programs
    Human Immunology, 2018
    Co-Authors: Anajane G. Smith, Shalini Pereira, Wyatt Nelson, Andres Jaramillo, Faisal Khan, Noureddine Berka, Marcelo J Pando, Maria Bettinotti, Medhat Askar
    Abstract:

    Aim Many laboratories use a 2-tier HLA typing process: a first pass intermediate resolution and then high resolution, when clinically necessary. SSP or qPCR provide rapid typing for deceased donor workup; SSOP is widely employed for higher volumes; and Sanger sequencing has been the gold standard for high resolution. However, SSOP and Sanger SBT often yield ambiguous results and resolution is expensive and time consuming. Next generation sequencing offers a single pass technology to achieve unambiguous HLA allele assignments. We compared commercial SSOP and NGS systems with respect to accuracy, turnaround time, effort and resolution level. Methods Five laboratories submitted coded, blinded samples, previously typed by SSOP at each institute, to a separate lab for NGS of HLA-A, B, C at exons 1–7, DRB1, DRB3/4/5, DQA1, DQB1, DPB1 at exons 1–4, and DPA1 at exons 2–4. For up to 24 samples by SSOP or up to 48 samples by NGS, benchwork is completed by one technologist on day 1 with results available for reporting on day 2. Results At the SSOP resolution level, results were concordant except for 11 SSOP assignments in 8 specimens due to false probe reactions at DRB1, DRB5, DQA1, DQB1, and DPB1. NGS identified 21 novel sequences: one with a multi-exon deletion and 20 with SNP polymorphisms in HLA-C, DPA1, DPB1, DQA1, DRB1, DRB3, DRB4, and DRB5 alleles. Across the highly polymorphic HLA-A, B, C, DRB1 loci, only 1% of intermediate resolution, IR, SSOP results were unambiguous. Even higher resolution, HR, SSOP by 1 lab gave only 17% specific allele assignments. In contrast, over 99% of NGS results were specific unambiguous genotypes. Across all loci, NGS typing was specific except for certain discrete diploid ambiguities, also found in SSOP. Conclusions This study provides a compelling rationale for implementing NGS for single pass HLA analysis with accurate, 2 day turnaround, which includes the high resolution, unambiguous genotyping critical for unrelated donor HCT and that may be required for sensitized patients with allele specific antibodies. A.G. Smith: 2. Consultant; Company/Organization; Scisco Genetics Inc. S.E. Pereira: 4. Scientific/Medical Advisor; Company/Organization; Scisco Genetics Inc. C. Pyo: 4. Scientific/Medical Advisor; Company/Organization; Scisco Genetics Inc. W. Nelson: 5. Employee; Company/Organization; Scisco Genetics Inc. M. Bettinotti: 3. Speaker’s Bureau; Company/Organization; One Lambda ThermoFisher. M.Z. Askar: 3. Speaker’s Bureau; Company/Organization; Immucor. 4. Scientific/Medical Advisor; Company/Organization; Illumina. D.E. Geraghty: 6. Stock Shareholder; Company/Organization; Scisco Genetics Inc. Download high-res image (283KB) Download full-size image

  • P099 Comparison of ssop versus ngs for typing of HLA-A, B, C, DRB1, DRB3/B4/B5, DQA1, DQB1, DPA1, DPB1: Toward single pass high resolution hla typing in support of solid organ and hematopoietic cell transplant programs
    Human Immunology, 2018
    Co-Authors: Anajane G. Smith, Shalini Pereira, Andres Jaramillo, Faisal Khan, Noureddine Berka, Marcelo J Pando, Maria Bettinotti, Chul-woo Pyo, Wyatt C. Nelson, Medhat Askar
    Abstract:

    Aim Many laboratories use a 2-tier HLA typing process: a first pass intermediate resolution and then high resolution, when clinically necessary. SSP or qPCR provide rapid typing for deceased donor workup; SSOP is widely employed for higher volumes; and Sanger sequencing has been the gold standard for high resolution. However, SSOP and Sanger SBT often yield ambiguous results and resolution is expensive and time consuming. Next generation sequencing offers a single pass technology to achieve unambiguous HLA allele assignments. We compared commercial SSOP and NGS systems with respect to accuracy, turnaround time, effort and resolution level. Methods Five laboratories submitted coded, blinded samples, previously typed by SSOP at each institute, to a separate lab for NGS of HLA-A, B, C at exons 1–7, DRB1, DRB3/4/5, DQA1, DQB1, DPB1 at exons 1–4, and DPA1 at exons 2–4. For up to 24 samples by SSOP or up to 48 samples by NGS, benchwork is completed by one technologist on day 1 with results available for reporting on day 2. Results At the SSOP resolution level, results were concordant except for 11 SSOP assignments in 8 specimens due to false probe reactions at DRB1, DRB5, DQA1, DQB1, and DPB1. NGS identified 21 novel sequences: one with a multi-exon deletion and 20 with SNP polymorphisms in HLA-C, DPA1, DPB1, DQA1, DRB1, DRB3, DRB4, and DRB5 alleles. Across the highly polymorphic HLA-A, B, C, DRB1 loci, only 1% of intermediate resolution, IR, SSOP results were unambiguous. Even higher resolution, HR, SSOP by 1 lab gave only 17% specific allele assignments. In contrast, over 99% of NGS results were specific unambiguous genotypes. Across all loci, NGS typing was specific except for certain discrete diploid ambiguities, also found in SSOP. Conclusions This study provides a compelling rationale for implementing NGS for single pass HLA analysis with accurate, 2 day turnaround, which includes the high resolution, unambiguous genotyping critical for unrelated donor HCT and that may be required for sensitized patients with allele specific antibodies. A.G. Smith: 2. Consultant; Company/Organization; Scisco Genetics Inc. S.E. Pereira: 4. Scientific/Medical Advisor; Company/Organization; Scisco Genetics Inc. C. Pyo: 4. Scientific/Medical Advisor; Company/Organization; Scisco Genetics Inc. W. Nelson: 5. Employee; Company/Organization; Scisco Genetics Inc. M. Bettinotti: 3. Speaker’s Bureau; Company/Organization; One Lambda ThermoFisher. M.Z. Askar: 3. Speaker’s Bureau; Company/Organization; Immucor. 4. Scientific/Medical Advisor; Company/Organization; Illumina. D.E. Geraghty: 6. Stock Shareholder; Company/Organization; Scisco Genetics Inc. Download : Download high-res image (283KB) Download : Download full-size image

  • common and well documented hla alleles 2012 update to the cwd catalogue
    Tissue Antigens, 2013
    Co-Authors: Steven J Mack, Shalini Pereira, Pedro Cano, Jill A Hollenbach, C K Hurley, D Middleton, M E Moraes, Jane Kempenich, Elaine F Reed, Michelle Setterholm
    Abstract:

    We have updated the catalogue of common and well-documented (CWD) human leukocyte antigen (HLA) alleles to reflect current understanding of the prevalence of specific allele sequences. The original CWD catalogue designated 721 alleles at the HLA-A, -B, -C, -DRB1, -DRB3/4/5, -DQA1, -DQB1, and -DPB1 loci in IMGT (IMmunoGeneTics)/HLA Database release 2.15.0 as being CWD. The updated CWD catalogue designates 1122 alleles at the HLA-A, -B, -C, -DRB1, -DRB3/4/5, -DQA1, -DQB1, -DPA1 and -DPB1 loci as being CWD, and represents 14.3% of the HLA alleles in IMGT/HLA Database release 3.9.0. In particular, we identified 415 of these alleles as being 'common' (having known frequencies) and 707 as being 'well-documented' on the basis of ~140,000 sequence-based typing observations and available HLA haplotype data. Using these allele prevalence data, we have also assigned CWD status to specific G and P designations. We identified 147/151 G groups and 290/415 P groups as being CWD. The CWD catalogue will be updated on a regular basis moving forward, and will incorporate changes to the IMGT/HLA Database as well as empirical data from the histocompatibility and immunogenetics community. This version 2.0.0 of the CWD catalogue is available online at cwd.immunogenomics.org, and will be integrated into the Allele Frequencies Net Database, the IMGT/HLA Database and National Marrow Donor Program's bioinformatics web pages.

Marcelo J Pando - One of the best experts on this subject based on the ideXlab platform.

  • p099 comparison of ssop versus ngs for typing of hla a b c drb1 drb3 b4 b5 dqa1 dqb1 dpa1 dpb1 toward single pass high resolution hla typing in support of solid organ and hematopoietic cell transplant programs
    Human Immunology, 2018
    Co-Authors: Anajane G. Smith, Shalini Pereira, Wyatt Nelson, Andres Jaramillo, Faisal Khan, Noureddine Berka, Marcelo J Pando, Maria Bettinotti, Medhat Askar
    Abstract:

    Aim Many laboratories use a 2-tier HLA typing process: a first pass intermediate resolution and then high resolution, when clinically necessary. SSP or qPCR provide rapid typing for deceased donor workup; SSOP is widely employed for higher volumes; and Sanger sequencing has been the gold standard for high resolution. However, SSOP and Sanger SBT often yield ambiguous results and resolution is expensive and time consuming. Next generation sequencing offers a single pass technology to achieve unambiguous HLA allele assignments. We compared commercial SSOP and NGS systems with respect to accuracy, turnaround time, effort and resolution level. Methods Five laboratories submitted coded, blinded samples, previously typed by SSOP at each institute, to a separate lab for NGS of HLA-A, B, C at exons 1–7, DRB1, DRB3/4/5, DQA1, DQB1, DPB1 at exons 1–4, and DPA1 at exons 2–4. For up to 24 samples by SSOP or up to 48 samples by NGS, benchwork is completed by one technologist on day 1 with results available for reporting on day 2. Results At the SSOP resolution level, results were concordant except for 11 SSOP assignments in 8 specimens due to false probe reactions at DRB1, DRB5, DQA1, DQB1, and DPB1. NGS identified 21 novel sequences: one with a multi-exon deletion and 20 with SNP polymorphisms in HLA-C, DPA1, DPB1, DQA1, DRB1, DRB3, DRB4, and DRB5 alleles. Across the highly polymorphic HLA-A, B, C, DRB1 loci, only 1% of intermediate resolution, IR, SSOP results were unambiguous. Even higher resolution, HR, SSOP by 1 lab gave only 17% specific allele assignments. In contrast, over 99% of NGS results were specific unambiguous genotypes. Across all loci, NGS typing was specific except for certain discrete diploid ambiguities, also found in SSOP. Conclusions This study provides a compelling rationale for implementing NGS for single pass HLA analysis with accurate, 2 day turnaround, which includes the high resolution, unambiguous genotyping critical for unrelated donor HCT and that may be required for sensitized patients with allele specific antibodies. A.G. Smith: 2. Consultant; Company/Organization; Scisco Genetics Inc. S.E. Pereira: 4. Scientific/Medical Advisor; Company/Organization; Scisco Genetics Inc. C. Pyo: 4. Scientific/Medical Advisor; Company/Organization; Scisco Genetics Inc. W. Nelson: 5. Employee; Company/Organization; Scisco Genetics Inc. M. Bettinotti: 3. Speaker’s Bureau; Company/Organization; One Lambda ThermoFisher. M.Z. Askar: 3. Speaker’s Bureau; Company/Organization; Immucor. 4. Scientific/Medical Advisor; Company/Organization; Illumina. D.E. Geraghty: 6. Stock Shareholder; Company/Organization; Scisco Genetics Inc. Download high-res image (283KB) Download full-size image

  • P099 Comparison of ssop versus ngs for typing of HLA-A, B, C, DRB1, DRB3/B4/B5, DQA1, DQB1, DPA1, DPB1: Toward single pass high resolution hla typing in support of solid organ and hematopoietic cell transplant programs
    Human Immunology, 2018
    Co-Authors: Anajane G. Smith, Shalini Pereira, Andres Jaramillo, Faisal Khan, Noureddine Berka, Marcelo J Pando, Maria Bettinotti, Chul-woo Pyo, Wyatt C. Nelson, Medhat Askar
    Abstract:

    Aim Many laboratories use a 2-tier HLA typing process: a first pass intermediate resolution and then high resolution, when clinically necessary. SSP or qPCR provide rapid typing for deceased donor workup; SSOP is widely employed for higher volumes; and Sanger sequencing has been the gold standard for high resolution. However, SSOP and Sanger SBT often yield ambiguous results and resolution is expensive and time consuming. Next generation sequencing offers a single pass technology to achieve unambiguous HLA allele assignments. We compared commercial SSOP and NGS systems with respect to accuracy, turnaround time, effort and resolution level. Methods Five laboratories submitted coded, blinded samples, previously typed by SSOP at each institute, to a separate lab for NGS of HLA-A, B, C at exons 1–7, DRB1, DRB3/4/5, DQA1, DQB1, DPB1 at exons 1–4, and DPA1 at exons 2–4. For up to 24 samples by SSOP or up to 48 samples by NGS, benchwork is completed by one technologist on day 1 with results available for reporting on day 2. Results At the SSOP resolution level, results were concordant except for 11 SSOP assignments in 8 specimens due to false probe reactions at DRB1, DRB5, DQA1, DQB1, and DPB1. NGS identified 21 novel sequences: one with a multi-exon deletion and 20 with SNP polymorphisms in HLA-C, DPA1, DPB1, DQA1, DRB1, DRB3, DRB4, and DRB5 alleles. Across the highly polymorphic HLA-A, B, C, DRB1 loci, only 1% of intermediate resolution, IR, SSOP results were unambiguous. Even higher resolution, HR, SSOP by 1 lab gave only 17% specific allele assignments. In contrast, over 99% of NGS results were specific unambiguous genotypes. Across all loci, NGS typing was specific except for certain discrete diploid ambiguities, also found in SSOP. Conclusions This study provides a compelling rationale for implementing NGS for single pass HLA analysis with accurate, 2 day turnaround, which includes the high resolution, unambiguous genotyping critical for unrelated donor HCT and that may be required for sensitized patients with allele specific antibodies. A.G. Smith: 2. Consultant; Company/Organization; Scisco Genetics Inc. S.E. Pereira: 4. Scientific/Medical Advisor; Company/Organization; Scisco Genetics Inc. C. Pyo: 4. Scientific/Medical Advisor; Company/Organization; Scisco Genetics Inc. W. Nelson: 5. Employee; Company/Organization; Scisco Genetics Inc. M. Bettinotti: 3. Speaker’s Bureau; Company/Organization; One Lambda ThermoFisher. M.Z. Askar: 3. Speaker’s Bureau; Company/Organization; Immucor. 4. Scientific/Medical Advisor; Company/Organization; Illumina. D.E. Geraghty: 6. Stock Shareholder; Company/Organization; Scisco Genetics Inc. Download : Download high-res image (283KB) Download : Download full-size image

Andres Jaramillo - One of the best experts on this subject based on the ideXlab platform.

  • p099 comparison of ssop versus ngs for typing of hla a b c drb1 drb3 b4 b5 dqa1 dqb1 dpa1 dpb1 toward single pass high resolution hla typing in support of solid organ and hematopoietic cell transplant programs
    Human Immunology, 2018
    Co-Authors: Anajane G. Smith, Shalini Pereira, Wyatt Nelson, Andres Jaramillo, Faisal Khan, Noureddine Berka, Marcelo J Pando, Maria Bettinotti, Medhat Askar
    Abstract:

    Aim Many laboratories use a 2-tier HLA typing process: a first pass intermediate resolution and then high resolution, when clinically necessary. SSP or qPCR provide rapid typing for deceased donor workup; SSOP is widely employed for higher volumes; and Sanger sequencing has been the gold standard for high resolution. However, SSOP and Sanger SBT often yield ambiguous results and resolution is expensive and time consuming. Next generation sequencing offers a single pass technology to achieve unambiguous HLA allele assignments. We compared commercial SSOP and NGS systems with respect to accuracy, turnaround time, effort and resolution level. Methods Five laboratories submitted coded, blinded samples, previously typed by SSOP at each institute, to a separate lab for NGS of HLA-A, B, C at exons 1–7, DRB1, DRB3/4/5, DQA1, DQB1, DPB1 at exons 1–4, and DPA1 at exons 2–4. For up to 24 samples by SSOP or up to 48 samples by NGS, benchwork is completed by one technologist on day 1 with results available for reporting on day 2. Results At the SSOP resolution level, results were concordant except for 11 SSOP assignments in 8 specimens due to false probe reactions at DRB1, DRB5, DQA1, DQB1, and DPB1. NGS identified 21 novel sequences: one with a multi-exon deletion and 20 with SNP polymorphisms in HLA-C, DPA1, DPB1, DQA1, DRB1, DRB3, DRB4, and DRB5 alleles. Across the highly polymorphic HLA-A, B, C, DRB1 loci, only 1% of intermediate resolution, IR, SSOP results were unambiguous. Even higher resolution, HR, SSOP by 1 lab gave only 17% specific allele assignments. In contrast, over 99% of NGS results were specific unambiguous genotypes. Across all loci, NGS typing was specific except for certain discrete diploid ambiguities, also found in SSOP. Conclusions This study provides a compelling rationale for implementing NGS for single pass HLA analysis with accurate, 2 day turnaround, which includes the high resolution, unambiguous genotyping critical for unrelated donor HCT and that may be required for sensitized patients with allele specific antibodies. A.G. Smith: 2. Consultant; Company/Organization; Scisco Genetics Inc. S.E. Pereira: 4. Scientific/Medical Advisor; Company/Organization; Scisco Genetics Inc. C. Pyo: 4. Scientific/Medical Advisor; Company/Organization; Scisco Genetics Inc. W. Nelson: 5. Employee; Company/Organization; Scisco Genetics Inc. M. Bettinotti: 3. Speaker’s Bureau; Company/Organization; One Lambda ThermoFisher. M.Z. Askar: 3. Speaker’s Bureau; Company/Organization; Immucor. 4. Scientific/Medical Advisor; Company/Organization; Illumina. D.E. Geraghty: 6. Stock Shareholder; Company/Organization; Scisco Genetics Inc. Download high-res image (283KB) Download full-size image

  • P099 Comparison of ssop versus ngs for typing of HLA-A, B, C, DRB1, DRB3/B4/B5, DQA1, DQB1, DPA1, DPB1: Toward single pass high resolution hla typing in support of solid organ and hematopoietic cell transplant programs
    Human Immunology, 2018
    Co-Authors: Anajane G. Smith, Shalini Pereira, Andres Jaramillo, Faisal Khan, Noureddine Berka, Marcelo J Pando, Maria Bettinotti, Chul-woo Pyo, Wyatt C. Nelson, Medhat Askar
    Abstract:

    Aim Many laboratories use a 2-tier HLA typing process: a first pass intermediate resolution and then high resolution, when clinically necessary. SSP or qPCR provide rapid typing for deceased donor workup; SSOP is widely employed for higher volumes; and Sanger sequencing has been the gold standard for high resolution. However, SSOP and Sanger SBT often yield ambiguous results and resolution is expensive and time consuming. Next generation sequencing offers a single pass technology to achieve unambiguous HLA allele assignments. We compared commercial SSOP and NGS systems with respect to accuracy, turnaround time, effort and resolution level. Methods Five laboratories submitted coded, blinded samples, previously typed by SSOP at each institute, to a separate lab for NGS of HLA-A, B, C at exons 1–7, DRB1, DRB3/4/5, DQA1, DQB1, DPB1 at exons 1–4, and DPA1 at exons 2–4. For up to 24 samples by SSOP or up to 48 samples by NGS, benchwork is completed by one technologist on day 1 with results available for reporting on day 2. Results At the SSOP resolution level, results were concordant except for 11 SSOP assignments in 8 specimens due to false probe reactions at DRB1, DRB5, DQA1, DQB1, and DPB1. NGS identified 21 novel sequences: one with a multi-exon deletion and 20 with SNP polymorphisms in HLA-C, DPA1, DPB1, DQA1, DRB1, DRB3, DRB4, and DRB5 alleles. Across the highly polymorphic HLA-A, B, C, DRB1 loci, only 1% of intermediate resolution, IR, SSOP results were unambiguous. Even higher resolution, HR, SSOP by 1 lab gave only 17% specific allele assignments. In contrast, over 99% of NGS results were specific unambiguous genotypes. Across all loci, NGS typing was specific except for certain discrete diploid ambiguities, also found in SSOP. Conclusions This study provides a compelling rationale for implementing NGS for single pass HLA analysis with accurate, 2 day turnaround, which includes the high resolution, unambiguous genotyping critical for unrelated donor HCT and that may be required for sensitized patients with allele specific antibodies. A.G. Smith: 2. Consultant; Company/Organization; Scisco Genetics Inc. S.E. Pereira: 4. Scientific/Medical Advisor; Company/Organization; Scisco Genetics Inc. C. Pyo: 4. Scientific/Medical Advisor; Company/Organization; Scisco Genetics Inc. W. Nelson: 5. Employee; Company/Organization; Scisco Genetics Inc. M. Bettinotti: 3. Speaker’s Bureau; Company/Organization; One Lambda ThermoFisher. M.Z. Askar: 3. Speaker’s Bureau; Company/Organization; Immucor. 4. Scientific/Medical Advisor; Company/Organization; Illumina. D.E. Geraghty: 6. Stock Shareholder; Company/Organization; Scisco Genetics Inc. Download : Download high-res image (283KB) Download : Download full-size image